11,993 Shares in iRadimed Corporation $IRMD Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC bought a new stake in shares of iRadimed Corporation (NASDAQ:IRMD) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,993 shares of the medical equipment provider’s stock, valued at approximately $1,130,000.

A number of other hedge funds have also recently modified their holdings of IRMD. Farther Finance Advisors LLC raised its holdings in shares of iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 397 shares during the period. Quarry LP purchased a new position in iRadimed during the 3rd quarter valued at $40,000. CWM LLC boosted its holdings in iRadimed by 19.5% during the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after acquiring an additional 107 shares during the period. Tower Research Capital LLC TRC grew its position in iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares during the last quarter. Finally, Global Retirement Partners LLC bought a new position in iRadimed in the 4th quarter valued at $85,000. Institutional investors own 92.34% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on IRMD shares. Wall Street Zen lowered shares of iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings downgraded shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $120.00.

iRadimed Stock Performance

iRadimed stock opened at $86.38 on Tuesday. The company has a market capitalization of $1.10 billion, a PE ratio of 48.26 and a beta of 0.90. The company has a 50 day moving average price of $92.85 and a 200-day moving average price of $94.03. iRadimed Corporation has a fifty-two week low of $67.84 and a fifty-two week high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to analysts’ expectations of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, analysts forecast that iRadimed Corporation will post 1.98 earnings per share for the current year.

iRadimed Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Friday, August 14th. iRadimed’s dividend payout ratio is currently 44.69%.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.